Powder: -20°C for 3 years | In solvent: -80°C for 1 year
LT052 is a highly active and selective inhibitor of BET BD1 with an IC 50 of 87.7 nM. LT052 exhibits nanomolar BRD4 BD1 potency and 138-fold selectivity over BRD4 BD2 (IC 50 =12.130 μM). LT052 has anti-inflammatory activity and can be used for acute gout arthritis research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
25 mg | 6-8 weeks | $ 1,490.00 | |
50 mg | 6-8 weeks | $ 2,480.00 |
Description | LT052 is a highly active and selective inhibitor of BET BD1 with an IC 50 of 87.7 nM. LT052 exhibits nanomolar BRD4 BD1 potency and 138-fold selectivity over BRD4 BD2 (IC 50 =12.130 μM). LT052 has anti-inflammatory activity and can be used for acute gout arthritis research [1]. |
Targets&IC50 | BRD3 BD1:246.3 nM, BRPF1B:567.5 nM, BRDT BD1:357.1 nM, BRD4 BD1:87.7 nM |
In vitro | LT052 (1 μM) inhibits NF-κB transcriptional activity in HUVECs cells and inhibit nitric oxide (NO) production (inhibition rate: 101.89%) in RAW264.7 cells. In the evaluation of in vitro inflammatory activity, LT052 maintains comparable or better anti-inflammatory activity than the pan-BET inhibitor (JQ1) compared to the protein weak activity [1].LT052 displays the highinhibitory activity against BRD4(1) (IC 50 : 87.7±4.9 nM), BRD3(1) (IC 50 : 246.3±20.2 nM), and BRDT(1) (IC 50 : 357.1±8.3 nM). LT052 also shows inhibitory activities against BRPF1b (IC 50 : 567.5±16.9 nM). Moreover, LT052 shows a 238-fold selectivity toward BD1 over BD2 with K d of 105 nM and >25 μM for BD1 and BD2, respectively [1].LT052 (1 μM; 1 hour) inhibits MSU-induced pyroptosis of THP-1 cells through BRD4/NF-κB/NLRP3 signaling pathways [1]. |
In vivo | LT052 (1 mg/kg; intra-articular) suppresses synovial hyperplasia and severe neutrophil infiltration that has a good therapeutic effect on MSU-induced acute gouty arthritis [1]. LT052 suppresses pyroptosis of macrophages in rat synovial tissues through regulating BRD4/NF-κB/NLRP3 signaling pathway [1]. LT052 has a high clearance rate in the range of 93.517 μL/min/mg proteins to 146.685 μL/min/mg proteins in liver microsomes of multiple species (human, monkey, dog, rat). Overall, LT052 exhibits moderately stable levels of in vitro liver microsomal metabolism [1]. Animal Model: Male Adult Sprague-Dawley rats (250-280 g) (acute gouty arthritis animal models) [1] Dosage: 1 mg/kg Administration: Intra-articular injection Result: Restored the joint circumference to normal level. |
Molecular Weight | 449.48 |
Formula | C22H19N5O4S |
CAS No. | 2543545-44-2 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
LT052 2543545-44-2 Chromatin/Epigenetic Epigenetic Reader Domain LT 052 LT-052 inhibitor inhibit